Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Gefitinib, MEDI4736; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Seattle, Washington

Conditions: Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash; Drug · Other
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Kidney Failure, Chronic
Interventions: ticagrelor; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more

Conditions: Relative Bioavailability
Interventions: BDA MDI 160/180 mcg, Pulmicort Flexhaler 180 mcg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: MEDI2070, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 26
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 22 more

Conditions: Influenza
Interventions: Trivalent Influenza Virus Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Non - Small Cell Lung Cancer NSCLC
Interventions: MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 33
States / cities: Chandler, Arizona • Anaheim, California • Duarte, California + 29 more

Conditions: NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
Interventions: AZD9150, Acalabrutinib, AZD6738, Hu5F9-G4, Rituximab, AZD5153; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 7 more

Conditions: Healthy Volunteer
Interventions: AZD8529, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuropathic Pain
Interventions: AZD2423, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 11 more

Conditions: COVID-19
Interventions: AZD7442, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 88
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more

Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions: AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Raised Intraocular Pressure
Interventions: AZD4017, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Newport Beach, California • Atlanta, Georgia • Morrow, Georgia + 4 more

Conditions: Idiopathic Dilated Cardiomyopathy
Interventions: Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 2
States / cities: Denver, Colorado • Salt Lake City, Utah

Conditions: Type 2 Diabetes Mellitus
Interventions: AZD1656, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Puberty, Precocious
Interventions: Bicalutamide, Anastrozole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 13 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Obinutuzumab, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus, High Blood Sugar
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Advanced Haematological Malignancies
Interventions: AZD4573, Acalabrutinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Duarte, California • La Jolla, California • Houston, Texas + 1 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 110
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Gefitinib, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 35
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 32 more

Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Interventions: AZD4573; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more

Conditions: Moderate to Severe Asthma
Interventions: Tezepelumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more

Search by objective public record fields.

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

AZD8529 Single Ascending Dose Study

A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Iressa Versus Docetaxel (Taxotere)

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma